polymorphism (SNP) in the Kv1.3 gene has also been associated with decreased insulin sensitivity and impaired glucose tolerance (Tschritter, Clin Endocrinol Metab 91: 654-8, 2006).

Kv1.3 is also expressed in proliferating human and mouse smooth muscle cells. Inhibitors of Kv1.3 may be effective in smooth muscle proliferative disorders such as restenosis, e.g. in patients following vascular surgery (e.g. angioplasty). Kv1.3 inhibitors have been shown to inhibit calcium entry, reduce smooth muscle cell migration, and inhibit neointimal hyperplasia in ex vivo human vein samples (Cheong et al., Cardiovasc. Res. 89:282-9, 2011).

Further evidence suggests that Kv1.3 channels are involved in the activation and/or proliferation of many types of cells, including tumor cells (Bielanska et al., Curr. Cancer Drug Targets 9:904-14, 2009), microglia (Khanna et al., Am. J. Physiol. Cell Physiol. 280: C796-806, 2001) and differentiation of neuronal progenitor cells (Wang et al., J. Neurosci. 30:5020-7, 2010). Kv1.3 inhibitors may therefore be beneficial in the treatment of neuroinflammatory and neurodegenerative disorders, and cancers.

Kv1.3 is part of a sub-family of closely related potassium channels, designated Kv1.1 to Kv1.8. When dealing with large homologous families, it is always desirable for an inhibitor to be as selective and specific as possible for the desired target, to improve efficacy and safety, and avoid undesirable off-target effects. The most specific Kv1.3 inhibitors identified to date are venom peptides derived from various types of venomous organisms, such as snakes, arachnids (such as scorpions and spiders), sea anemones, etc. Such Kv1.3 inhibitors include the peptides ShK, Oskl, margatoxin and kaliotoxin, reviewed by Chandy et al., Trends in Pharmacol. Sci. 25:280-9, 2004. See also Abdel-Mottaleb et al., Toxicon 51:1424-30, 2008, and Mouhat et al., Biochem. J. 385(Pt 1):95-104, 2005.

Various attempts to engineer toxin peptides for particular properties, including specificity or potency, have been described, e.g. in WO2006/002850, WO2006/042151, WO2008/088422, WO2006/116156, WO2010/105184 and WO2014/116937.

SUMMARY

The disclosure relates to Kv1.3 inhibitors derived from a toxin peptide of the scorpion *Parabuthus transvaalicus.* The toxin peptide has the amino acid sequence QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR (SEQ ID NO 1).

Amongst other desirable properties, this molecule and derivatives or variants thereof have been found to be extremely selective inhibitors for the Kv1.3 potassium ion channel over other voltage-gated potassium channels, and typically also have high potency at blocking the Kv1.3

channel. Peptides that are highly selective for the Kv1.3 channel, such as those derived from PaT1, have the particular advantage of selectively targeting cells expressing Kv1.3 channels, such as specific populations of effector memory T cells. This selectivity thus gives Kv1.3 inhibitors derived from PaT1 the potential for targeted therapeutic effects.

Kv1.3 inhibitors based on the PaT1 toxin peptide have a short half-life in the body of a subject. For instance, Example 6 herein shows that such Kv1.3 inhibitors have a half-life of about 1 hour in a rat model organism. However, the present inventors have surprisingly found that, despite this short half-life, the Kv1.3 inhibitors described herein have a long-lasting effect on T cells. In particular, Example 8 herein shows that inflammation is reduced in a rat ear inflammation model up to 7 days after treatment with the Kv1.3 inhibitor. Additionally, Example 9 herein shows that treatment with a Kv1.3 inhibitor once every 5 days reduces inflammation in a rat model of arthritis. Without wishing to be bound by theory, it is hypothesised that the Kv1.3 inhibitor somehow, through its interaction with the Kv1.3 ion channel, “reprograms” T cells to remain inactive for an extended period, thereby suppressing inflammation for multiple days.

These surprising findings support the concept of treating a subject suffering from a disease, condition or disorder that may be treated using a Kv1.3 inhibitor as described herein following a regime of administering the inhibitor at roughly weekly intervals (i.e. once every 2 to 8 days). It is advantageous to increase as much as possible the period between administrations of an active compound as this saves time and effort (as fewer administrations need to be carried out over a given period) and expense (as less active compound needs to be used over a given period). Particularly in the case of active compounds administered by certain routes, such as subcutaneous injection, a longer interval between administrations also increases patient comfort and may thereby increase patient compliance with the treatment regime. For example, administering the Kv1.3 inhibitor in accordance with the present disclosure (i.e. once every 2 to 8 days) is superior to administering the inhibitor daily, for the above reasons. An unexpected finding described in the present disclosure is that administering a Kv1.3 inhibitor as described herein once every 2 to 8 days is possible despite their short *in vivo* half-life, as an effect of the inhibitor (such as reduced inflammation) is observed multiple days after administration. In one example, the present disclosure refers to the use of a Kv1.3 inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease or disorder in a subject, wherein the Kv1.3 inhibitor comprises or consists of a peptide comprising or consisting of the sequence QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR (SEQ ID NO 1) or a variant

thereof, wherein the variant (a) has at least 70% sequence identity to SEQ ID NO 1, and/or (b) differs from SEQ ID NO 1 by up to nine substitutions, insertions and/or deletions in total, and wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 to 8 days.

In another aspect, the present disclosure refers to the use of a Kv1.3 inhibitor, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9, in the manufacture of a medicament for (a) inhibiting or reducing inflammation; or (b) inhibiting weight gain, promoting weight loss, reducing excess body weight or treating obesity; wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 to 8 days.

Accordingly, the disclosure provides a Kv1.3 inhibitor, or a pharmaceutically acceptable salt thereof, for use in a method of treating or preventing a disease or disorder in a subject, wherein the Kv1.3 inhibitor comprises or consists of a peptide comprising or consisting of the sequence QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR (SEQ ID NO 1) or a variant thereof, wherein the variant (a) has at least 65% sequence identity to SEQ ID NO 1, and/or (b) differs from SEQ ID NO 1 by up to nine substitutions, insertions and/or deletions in

CLAIMS

1. Use of a Kv1.3 inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease or disorder in a subject, wherein the Kv1.3 inhibitor comprises or consists of a peptide comprising or consisting of the sequence QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR (SEQ ID NO 1) or a variant thereof, wherein the variant

(a) has at least 70% sequence identity to SEQ ID NO 1, and/or

(b) differs from SEQ ID NO 1 by up to nine substitutions, insertions and/or deletions in total,

and wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 to 8 days.

2. The use according to claim 1, wherein the Kv1.3 inhibitor has an IC_{50} for human Kv1.3 potassium channel of 400 nM or less, preferably 300 nM or less, preferably 50 nM or less, preferably 15 nM or less, preferably 10 nM or less, preferably 5 nM or less, preferably 2 nM or less.

3. The use according to claim 1 or claim 2, wherein the variant has at least 70% sequence identity to SEQ ID NO 1, preferably at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO 1.

4. The use according to any one of claims 1 to 3, wherein the peptide comprises the following amino acids:

the amino acid at position 6 is C;

the amino acid at position 12 is C;

the amino acid at position 16 is C;

the amino acid at position 27 is C;

the amino acid at position 32 is C; and

the amino acid at position 34 is C;

preferably wherein also:

the amino acid at position 24 is F;

the amino acid at position 25 is G;

the amino acid at position 29 is N; and

the amino acid at position 31 is K.

5. The use according to any one of claims 1 to 4, wherein the variant differs from SEQ ID NO 1 by up to nine substitutions, insertions and/or deletions in total, preferably up to eight, up to seven, up to six, up to five, up to four, up to three or up to two substitutions, insertions and/or deletions in total or by one substitution, insertion or deletion in total.

6. The use according to any one of claims 1 to 5, wherein any substitutions or deletions in the variant of SEQ ID NO 1 are at amino acid positions selected from positions 1-5, 7-11, 13-15, 17-23, 26, 28, 30, 33 and 35-37 of SEQ ID NO 1, preferably at amino acid positions selected from positions 1, 2, 3, 4, 5, 7, 14, 18, 19, 28 and 37 of SEQ ID NO 1.

7. The use according to any one of claims 1 to 6, wherein the peptide comprises the following amino acids:

the amino acid at position 1 is H, N, P, p, Q, S, V or Y or is deleted;
the amino acid at position 2 is I, M or Nle or is deleted;
the amino acid at position 3 is D, E or S or is deleted;
the amino acid at position 4 is E, L, M, Nle, S or V or is deleted;
the amino acid at position 5 is R or K or is deleted;
the amino acid at position 7 is E, F, H, K, Orn, R, S, Y, 2,3-Diaminopropanoyl, 2,4-Diaminobutanoyl or 2-Amino-3-guanidinopropionyl;
the amino acid at position 8 is A, H, I, L, S or Y;
the amino acid at position 9 is F, L, P, S, Orn, V, Abu or 2,3-Diaminopropanoyl;
the amino acid at position 10 is K, P, Q, R or V;
the amino acid at position 11 is E or Q;
the amino acid at position 13 is A, E, G, K, L, Q or V;
the amino acid at position 14 is E, K, L, Q, V or 2-amino-5-carboxypentanoyl;
the amino acid at position 15 is K, L, P, S;
the amino acid at position 17 is K, L, R or Y or is deleted;
the amino acid at position 18 is A, D, G, K, Q, hQ, V or Y or is deleted;
the amino acid at position 19 is A, K, R or Y or is deleted;
the amino acid at position 20 is E, I, R or Y or is deleted;
the amino acid at position 21 is E, G, H or R;
the amino acid at position 22 is C, R or S;
the amino acid at position 23 is G, I, K, P or R;
the amino acid at position 26 is K or hK;
the amino acid at position 28 is M or Nle;
the amino acid at position 30 is G or K;
the amino acid at position 33 is H, K, R or V;

the amino acid at position 35 is Y, F(4-F), F(4-CH_3), F(4-NO_2) or F(4-NH_2);

the amino acid at position 36 is Q or P or is deleted; and/or

the amino acid at position 37 is C, G, R, S or (4-amino-5-hydroxypentyl)guanidine or is deleted.

8. The use according to any one of claims 1 to 7, wherein the peptide comprises or consists of one of the following sequences:

SEQ ID NO	Sequence
1	QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
2	QMDMRCSASVECKQKCLKAIGRGFGKCMNKKCKCYPR
3	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
4	NMDMRCSASVECKQKCLKAIGRGFGKCMNKKCKCYPR
5	MDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
6	DMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
7	P[Nle]E[Nle]RCYASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
8	NIDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
9	NMDVRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
10	NMDMRCSASVECKQKCKDAIGSIFGKCMNKKCKCYPR
11	GGNMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
12	NMEMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
13	SGNMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
14	N[Nle]DMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
15	NMD[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
16	NMDMRCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
17	NMDMRCSASVECKVKCLKAIGSIFGKCMNKKCKCYPR
18	NMDMRCSASVECKQLCLKAIGSIFGKCMNKKCKCYPR
19	NMDMRCSASVECKQKCKKAIGSIFGKCMNKKCKCYPR
20	NMDMRCSASVECKQKCLDAIGSIFGKCMNKKCKCYPR
21	NMDMRCSASVECKQKCLKAIRSIFGKCMNKKCKCYPR
22	NMDMRCSASVECKQKCLKAIESIFGKCMNKKCKCYPR
23	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPRRRTA
24	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPRHRRK
25	NMDMRCKASVECKQKCLKAIGSIFGKCMNKKCKCYPR
26	NMDMRCSISVECKQKCLKAIGSIFGKCMNKKCKCYPR
27	NMDMRCSASRECKQKCLKAIGSIFGKCMNKKCKCYPR
28	NMDMRCSASVQCKQKCLKAIGSIFGKCMNKKCKCYPR
29	NMDMRCSASVECLQKCLKAIGSIFGKCMNKKCKCYPR
30	NMDMRCSASVECAQKCLKAIGSIFGKCMNKKCKCYPR
31	NMDMRCSASVECKEKCLKAIGSIFGKCMNKKCKCYPR
32	NMDMRCSASVECKLKCLKAIGSIFGKCMNKKCKCYPR
33	NMDMRCSASVECKQKCLKAIHSIFGKCMNKKCKCYPR
34	NMDMRCSASVECKQKCLKAIGSKFGKCMNKKCKCYPR

35	NMDMRCSASVECKQKCLKAIGSRFGKCMNKKCKCYPR
36	NMDMRCSASVECKQKCLKAIGSIFGKCMNGKCKCYPR
37	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCHCYPR
38	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCVCYPR
39	N[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
40	N[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
41	P[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
42	N[Nle]D[Nle]RCRASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
43	N[Nle]D[Nle]RCSASVECEQKCLKAIGSIFGKC[Nle]NKKCKCYPR
44	N[Nle]D[Nle]RCSASVECQQKCLKAIGSIFGKC[Nle]NKKCKCYPR
45	N[Nle]D[Nle]RCSASVECKKKCLKAIGSIFGKC[Nle]NKKCKCYPR
46	N[Nle]S[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
47	N[Nle]D[Nle]RCSHSVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
48	N[Nle]D[Nle]RCSASVECKQSCLKAIGSIFGKC[Nle]NKKCKCYPR
49	N[Nle]D[Nle]RCSASVECKQKCKAIGSIFGKC[Nle]NKKCKCYPR
50	NMDMRCSASVECKQKCYKAIGSIFGKCMNKKCKCYPR
51	NMDMRCSASVECKQKCRKAIGSIFGKCMNKKCKCYPR
52	NMDMRCSASVECKQKCLAAIGSIFGKCMNKKCKCYPR
53	NMDMRCSASVECKQKCLYAIGSIFGKCMNKKCKCYPR
54	NMDMRCSASVECKQKCLAIGSIFGKCMNKKCKCYPR
55	NMDMRCSASVECKQKCLKYIGSIFGKCMNKKCKCYPR
56	NMDMRCSASVECKQKCLKRIGSIFGKCMNKKCKCYPR
57	NMDMRCSASVECKQKCLKIGSIFGKCMNKKCKCYPR
58	NMDMRCSASVECKQKCLKAYGSIFGKCMNKKCKCYPR
59	NMDMRCSASVECKQKCLKAEGSIFGKCMNKKCKCYPR
60	NMDMRCSASVECKQKCLKARGSIFGKCMNKKCKCYPR
61	NMDMRCSASVECKQKCLKAGSIFGKCMNKKCKCYPR
62	N[Nle]D[Nle]RCSASVECKQKCLKAIGSPFGKC[Nle]NKKCKCYPR
63	N[Nle]D[Nle]RCSASKECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
64	H[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
65	Y[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
66	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
67	V[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
68	S[Nle]D[Nle]RCSA[Abu]VECKQKCLKAIGSIFGKCMNKKCKCYPR
69	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFG[homo-Lys]CMNKKCKCYPR
70	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-NH2)]PR
71	S[Nle]D[Nle]RCSASVECGQKCLKAIGSIFGKCMNKKCKCYPR
72	S[Nle]D[Nle]RCSASVECVQKCLKAIGSIFGKCMNKKCKCYPR
73	S[Nle]D[Nle]RCSASVECK[2-Amino-5-carboxypentanoyl]KCLKAIGSIFGKCMNKKCKCYPR
74	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYQ
75	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCRCYPR
76	S[Nle]DERCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
77	S[Nle]D[Nle]RCSASVECKQKCLGAIGSIFGKCMNKKCKCYPR
78	S[Nle]D[Nle]RCSASVECKQKCLVAIGSIFGKCMNKKCKCYPR

79	S[Nle]D[Nle]RCSASVECAQSCLKAIGSIFGKCMNKKCKCYPR
80	S[Nle]D[Nle]RCSASVECAQKCLAAIGSIFGKCMNKKCKCYPR
81	S[Nle]D[Nle]RCSASVECAQLCLAAIGSIFGKCMNKKCKCYPR
82	P[Nle]E[Nle]RC[2,4-Diaminobutanoyl]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
83	P[Nle]D[Nle]RCSASVECKQKCLKAIGCIFGKC[Nle]NKKCKCYPC
84	S[Nle]D[Nle]RCSASVECKEKCLQAIGSIFGKC[Nle]NKKCKCYPR
85	P[Nle]D[Nle]RCSASVECKEKCL[homo-Gln]AIGSIFGKC[Nle]NKKCKCYPR
86	CSASVECKQKCLKAIGCIFGKC[Nle]NKKCKCYPC
87	S[Nle]D[Nle]RCSASVECKQKCLAAIGCIFGKC[Nle]NKKCKCYPC
88	P[Nle]E[Nle]RC[2-Amino-3-guanidinopropionyl]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
89	S[Nle]D[Nle]RCSALVECKQKCLKAIGSIFGKCMNKKCKCYPR
90	S[Nle]D[Nle]RCSAVVECKQKCLKAIGSIFGKCMNKKCKCYPR
91	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-F)]PR
92	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-NO_2)]PR
93	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-CH_3)]PR
94	[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
95	NID[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
96	PIE[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
97	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
98	P[Nle]E[Nle]RCSA[Orn]VECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
99	P[Nle]E[Nle]RCSASVECKQKCLLAIGSIFGKC[Nle]NKKCKCYPR
100	PIDERCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
101	PIE[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
102	P[Nle]D[Nle]RCSASVECAQKCLAAIGSIFGKCMNKKCKCYPR
103	P[Nle]E[Nle]RCSASVECAQKCLAAIGSIFGKC[Nle]NKKCKCYPR
104	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
105	P[Nle]E[Nle]RC[2,3-Diaminopropanoyl]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
106	RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
107	SKCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
108	LRCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
109	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPS
110	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYS
111	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYG
112	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCY
113	P[Nle]E[Nle]RC[Orn]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
114	P[Nle]E[Nle]RCHASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
115	LRCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
116	LRCSASVECKQKCLAAIGSIFGKCMNKKCKCYPR
117	CSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
118	P[Nle]E[Nle]RCSASVECKEKCLAAIGSIFGKC[Nle]NKKCKCYPR
119	p[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
120	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYR
121	[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR

122	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRR
123	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRY
124	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRL
125	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRH
126	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRE
127	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRKS
128	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRFE
129	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRHR
130	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRAK
131	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYP-[(4-amino-5-hydroxypentyl)guanidine]
132	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR-[4-amino-5-hydroxypentanamide]
133	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRST
134	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRRY
135	P[Nle]E[Nle]RCSSSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
136	P[Nle]E[Nle]RCSLSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
137	P[Nle]E[Nle]RCSAPVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
138	P[Nle]E[Nle]RCSASPECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
139	P[Nle]E[Nle]RCSASQECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
140	P[Nle]E[Nle]RCSASVECLQKCLAAIGSIFGKC[Nle]NKKCKCYPR
141	P[Nle]E[Nle]RCSASVECKQPCLAAIGSIFGKC[Nle]NKKCKCYPR
142	P[Nle]E[Nle]RCEASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
143	P[Nle]E[Nle]RCFASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
144	P[Nle]E[Nle]RCSYSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
145	P[Nle]E[Nle]RCSAFVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
146	P[Nle]E[Nle]RCSA[2,3-Diaminopropanoyl]VECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
147	P[Nle]E[Nle]RC[2,4-Diaminobutanoyl]ASVECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
148	P[Nle]E[Nle]RCRASVECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
149	P[Nle]E[Nle]RCSASRECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
150	P[Nle]E[Nle]RCSASVECKQKCLAKIGSIFGKC[Nle]NKKCKCYPR

9. The use according to any one of claims 1 to 8, wherein the peptide is selected from the following peptides:

SEQ ID NO	**Ptd No.**	**Peptide**
1	1	H-QMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
2	2	H-QMDMRC(1)SASVEC(2)KQKC(3)LKAIGRGFGKC(1)MNKKC(2)KC(3)YPR-OH
3	3	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
3	4	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
4	5	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGRGFGKC(1)MNKKC(2)KC(3)YPR-OH
5	6	H-MDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
6	7	H-DMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH

7	8	H-P[Nle]E[Nle]RC(1)YASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
8	9	H-NIDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
9	10	H-NMDVRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
10	11	H-NMDMRC(1)SASVEC(2)KQKC(3)KDAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
11	12	H-GGNMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
12	13	H-NMEMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
13	14	H-SGNMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
14	15	H-N[Nle]DMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
15	16	H-NMD[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
16	17	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
17	18	H-NMDMRC(1)SASVEC(2)KVKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
18	19	H-NMDMRC(1)SASVEC(2)KQLC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
19	20	H-NMDMRC(1)SASVEC(2)KQKC(3)KKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
20	21	H-NMDMRC(1)SASVEC(2)KQKC(3)LDAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
21	22	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIRSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
22	23	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIESIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
23	24	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPRRRTA-NH_2
24	25	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPRHRRK-NH_2
25	26	H-NMDMRC(1)KASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
26	27	H-NMDMRC(1)SISVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
27	28	H-NMDMRC(1)SASREC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
28	29	H-NMDMRC(1)SASVQC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
29	30	H-NMDMRC(1)SASVEC(2)LQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
30	31	H-NMDMRC(1)SASVEC(2)AQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
31	32	H-NMDMRC(1)SASVEC(2)KEKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
32	33	H-NMDMRC(1)SASVEC(2)KLKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
33	34	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIHSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
34	35	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSKFGKC(1)MNKKC(2)KC(3)YPR-NH_2
35	36	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSRFGKC(1)MNKKC(2)KC(3)YPR-NH_2
36	37	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNGKC(2)KC(3)YPR-NH_2
37	38	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)HC(3)YPR-NH_2
38	39	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)VC(3)YPR-NH_2
39	40	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
40	41	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
41	42	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
42	43	H-N[Nle]D[Nle]RC(1)RASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
43	44	H-N[Nle]D[Nle]RC(1)SASVEC(2)EQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
44	45	H-N[Nle]D[Nle]RC(1)SASVEC(2)QQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
45	46	H-N[Nle]D[Nle]RC(1)SASVEC(2)KKKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2

46	47	H-N[Nle]S[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
47	48	H-N[Nle]D[Nle]RC(1)SHSVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
48	49	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQSC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
49	50	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)KAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
50	51	H-NMDMRC(1)SASVEC(2)KQKC(3)YKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
51	52	H-NMDMRC(1)SASVEC(2)KQKC(3)RKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
52	53	H-NMDMRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
53	54	H-NMDMRC(1)SASVEC(2)KQKC(3)LYAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
54	55	H-NMDMRC(1)SASVEC(2)KQKC(3)LAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
55	56	H-NMDMRC(1)SASVEC(2)KQKC(3)LKYIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
56	57	H-NMDMRC(1)SASVEC(2)KQKC(3)LKRIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
57	58	H-NMDMRC(1)SASVEC(2)KQKC(3)LKIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
58	59	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAYGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
59	60	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAEGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
60	61	H-NMDMRC(1)SASVEC(2)KQKC(3)LKARGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
61	62	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
62	63	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSPFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
63	64	H-N[Nle]D[Nle]RC(1)SASKEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
64	65	H-H[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
65	66	H-Y[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
66	67	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
66	68	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
67	69	H-V[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
68	70	H-S[Nle]D[Nle]RC(1)SA[Abu]VEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
69	71	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFG[homo-Lys]C(1)MNKKC(2)KC(3)YPR-NH_2
70	72	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-NH_2)]PR-NH_2
71	73	H-S[Nle]D[Nle]RC(1)SASVEC(2)GQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
72	74	H-S[Nle]D[Nle]RC(1)SASVEC(2)VQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
73	75	H-S[Nle]D[Nle]RC(1)SASVEC(2)K[2-Amino-5-carboxypentanoyl]KC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2

74	76	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YQ-NH_2
75	77	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)RC(3)YPR-NH_2
76	78	H-S[Nle]DERC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
77	79	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LGAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
78	80	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LVAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
79	81	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQSC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
80	82	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
81	83	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQLC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
82	84	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
83	85	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
83	86	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-OH
84	87	H-S[Nle]D[Nle]RC(1)SASVEC(2)KEKC(3)LQAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
85	88	H-P[Nle]D[Nle]RC(1)SASVEC(2)KEKC(3)L[homo-Gln]AIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
86	89	H-C(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
87	90	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
88	91	H-P[Nle]E[Nle]RC(1)[2-Amino-3-guanidinopropionyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
89	92	H-S[Nle]D[Nle]RC(1)SALVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
90	93	H-S[Nle]D[Nle]RC(1)SAVVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
91	94	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-F)]PR-NH_2
92	95	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-NO_2)]PR-NH_2
93	96	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-CH_3)]PR-NH_2
94	97	H-[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
95	98	H-NID[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
96	99	H-PIE[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
97	100	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
97	101	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
98	102	H-P[Nle]E[Nle]RC(1)SA[Orn]VEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH

99	103	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LLAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
100	104	H-PIDERC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
101	105	H-PIE[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
102	106	H-P[Nle]D[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
103	107	H-P[Nle]E[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
104	108	H-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
104	109	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
105	110	H-P[Nle]E[Nle]RC(1)[2,3-Diaminopropanoyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
106	111	H-RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
106	112	Ac-RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
107	113	Ac-SKC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
108	114	Ac-LRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
108	115	H-LRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
109	116	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPS-NH_2
110	117	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YS-NH_2
111	118	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YG-NH_2
112	119	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)Y-NH_2
113	120	H-P[Nle]E[Nle]RC(1)[Orn]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
114	121	H-P[Nle]E[Nle]RC(1)HASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
115	122	Ac-LRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
116	123	Ac-LRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
117	124	H-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
118	125	H-P[Nle]E[Nle]RC(1)SASVEC(2)KEKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
119	126	H-p[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
120	127	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YR-OH
121	128	H-[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
122	129	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRR-OH
123	130	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRY-OH
124	131	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRL-OH
125	132	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRH-OH

126	133	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRE-OH
127	134	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRKS-OH
128	135	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRFE-OH
129	136	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRHR-OH
130	137	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRAK-OH
131	138	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YP-[(4-amino-5-hydroxypentyl)guanidine]
132	139	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-[4-amino-5-hydroxypentanamide]
133	140	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRST-OH
134	141	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRRY-OH
135	142	H-P[Nle]E[Nle]RC(1)SSSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
136	143	H-P[Nle]E[Nle]RC(1)SLSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
137	144	H-P[Nle]E[Nle]RC(1)SAPVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
138	145	H-P[Nle]E[Nle]RC(1)SASPEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
139	146	H-P[Nle]E[Nle]RC(1)SASQEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
140	147	H-P[Nle]E[Nle]RC(1)SASVEC(2)LQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
141	148	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQPC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
142	149	H-P[Nle]E[Nle]RC(1)EASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
143	150	H-P[Nle]E[Nle]RC(1)FASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
144	151	H-P[Nle]E[Nle]RC(1)SYSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
145	152	H-P[Nle]E[Nle]RC(1)SAFVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH

146	153	H-P[Nle]E[Nle]RC(1)SA[2,3-Diaminopropanoyl]VEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
147	154	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-OH
147	155	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
148	156	H-P[Nle]E[Nle]RC(1)RASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
149	157	H-P[Nle]E[Nle]RC(1)SASREC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
150	158	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAKIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH

10. The use according to any one of claims 1 to 9, wherein the disease or disorder is

(a) an inflammatory disease or disorder, preferably wherein the inflammatory disease or disorder is selected from an autoimmune disorder, an allergy or hypersensitivity, allograft rejection, transplant rejection, graft-versus-host disease, hay fever, asthma, anaphylaxis, allergic rhinitis, urticaria, eczema, alopecia areata, dermatomyositis, inclusion body myositis, polymyositis, ankylosing spondylitis, vasculitis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Sjogren's syndrome, systemic lupus erythematosus (SLE), uveitis, inflammatory fibrosis (e.g. scleroderma, lung fibrosis, cirrhosis), chronic obstructive pulmonary disease (COPD), hepatitis, chronic inflammatory demyelinating polyneuropathy, inflammatory bowel disease, colitis (e.g. Crohn's disease and ulcerative colitis), erythema, thyroiditis, psoriasis, atopic dermatitis, allergic contact dermatitis, scleroderma, glomerulonephritis, inflammatory bone resorption, multiple sclerosis and type 1 diabetes; or

(b) a metabolic disease or disorder; or

(c) selected from obesity, obesity-linked inflammation, obesity-linked gall bladder disease and obesity-induced sleep apnoea; or

(d) caused by or associated with impaired glucose control, preferably wherein the disease or disorder is selected from metabolic syndrome, insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose and type 2 diabetes; or

(e) a smooth muscle proliferative disorder, preferably wherein the smooth muscle proliferative disorder is restenosis; or

(f) a neuroinflammatory or neurodegenerative disease or disorder, preferably wherein the neuroinflammatory or neurodegenerative disease or disorder is selected from Alzheimer's disease, multiple sclerosis (MS), Parkinson's disease and amyotrophic lateral sclerosis (ALS); or

(g) cancer, preferably wherein the cancer is breast cancer, prostate cancer or lymphoma, preferably wherein the lymphoma is non-Hodgkin lymphoma (NHL), preferably wherein the NHL is selected from diffuse large B-cell lymphoma, follicular lymphoma, Burkitt lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, anaplastic large cell lymphoma, peripheral T-cell lymphoma, precursor T-lymphoblastic lymphoma and Sézary syndrome.

11. Use of a Kv1.3 inhibitor, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 9, in the manufacture of a medicament for

(a) inhibiting or reducing inflammation; or

(b) inhibiting weight gain, promoting weight loss, reducing excess body weight or treating obesity;

wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 to 8 days.

12. The use according to any one of claims 1 to 11, wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 to 7 days, once every 2 to 6 days, once every 2 to 5 days, once every 2 to 4 days, once every 2 to 3 days, once every 3 to 8 days, once every 3 to 7 days, once every 3 to 6 days, once every 3 to 5 days, once every 3 to 4 days, once every 4 to 8 days, once every 4 to 7 days, once every 4 to 6 days, once every 4 to 5 days, once every 5 to 8 days, once every 5 to 7 days, once every 5 to 6 days, once every 6 to 8 days, once every 6 to 7 days or once every 7 to 8 days.

13. The use according to any one of claims 1 to 12, wherein the Kv1.3 inhibitor is to be administered to the subject once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 7 days or once every 8 days, preferably once every 7 days.

14. The use according to any one of claims 1 to 13, wherein the Kv1.3 inhibitor is to be administered to the subject by injection, preferably by subcutaneous injection.

15. The use according to any one of claims 1 to 14, wherein the Kv1.3 inhibitor is to be administered to the subject at a dosage of 0.1 mg to 30.0 mg.

16. The use according to any one of claims 1 to 15, wherein the Kv1.3 inhibitor is to be administered to the subject at a dosage of 10 nmol/kg to 400 nmol/kg or at a dosage of 3 nmol/kg to 300 nmol/kg.

17. The use according to any one of claims 1 to 16, wherein the Kv1.3 inhibitor or pharmaceutically acceptable salt is in the form of a composition, preferably wherein the composition is a pharmaceutical composition, and preferably wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier, excipient or vehicle.

18. The use according to claim 17, wherein the composition comprises one or more peptides wherein each of the peptides comprises or consists of a sequence independently selected from the following sequences:

SEQ ID NO	Sequence
1	QMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
2	QMDMRCSASVECKQKCLKAIGRGFGKCMNKKCKCYPR
3	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
4	NMDMRCSASVECKQKCLKAIGRGFGKCMNKKCKCYPR
5	MDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
6	DMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
7	P[Nle]E[Nle]RCYASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
8	NIDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
9	NMDVRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
10	NMDMRCSASVECKQKCKDAIGSIFGKCMNKKCKCYPR
11	GGNMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
12	NMEMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
13	SGNMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
14	N[Nle]DMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
15	NMD[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
16	NMDMRCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
17	NMDMRCSASVECKVKCLKAIGSIFGKCMNKKCKCYPR
18	NMDMRCSASVECKQLCLKAIGSIFGKCMNKKCKCYPR
19	NMDMRCSASVECKQKCKKAIGSIFGKCMNKKCKCYPR
20	NMDMRCSASVECKQKCLDAIGSIFGKCMNKKCKCYPR
21	NMDMRCSASVECKQKCLKAIRSIFGKCMNKKCKCYPR
22	NMDMRCSASVECKQKCLKAIESIFGKCMNKKCKCYPR
23	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPRRRTA
24	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCKCYPRHRRK
25	NMDMRCKASVECKQKCLKAIGSIFGKCMNKKCKCYPR
26	NMDMRCSISVECKQKCLKAIGSIFGKCMNKKCKCYPR
27	NMDMRCSASRECKQKCLKAIGSIFGKCMNKKCKCYPR
28	NMDMRCSASVQCKQKCLKAIGSIFGKCMNKKCKCYPR
29	NMDMRCSASVECLQKCLKAIGSIFGKCMNKKCKCYPR
30	NMDMRCSASVECAQKCLKAIGSIFGKCMNKKCKCYPR
31	NMDMRCSASVECKEKCLKAIGSIFGKCMNKKCKCYPR
32	NMDMRCSASVECKLKCLKAIGSIFGKCMNKKCKCYPR

33	NMDMRCSASVECKQKCLKAIHSIFGKCMNKKCKCYPR
34	NMDMRCSASVECKQKCLKAIGSKFGKCMNKKCKCYPR
35	NMDMRCSASVECKQKCLKAIGSRFGKCMNKKCKCYPR
36	NMDMRCSASVECKQKCLKAIGSIFGKCMNGKCKCYPR
37	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCHCYPR
38	NMDMRCSASVECKQKCLKAIGSIFGKCMNKKCVCYPR
39	N[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
40	N[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
41	P[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
42	N[Nle]D[Nle]RCRASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
43	N[Nle]D[Nle]RCSASVECEQKCLKAIGSIFGKC[Nle]NKKCKCYPR
44	N[Nle]D[Nle]RCSASVECQQKCLKAIGSIFGKC[Nle]NKKCKCYPR
45	N[Nle]D[Nle]RCSASVECKKKCLKAIGSIFGKC[Nle]NKKCKCYPR
46	N[Nle]S[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
47	N[Nle]D[Nle]RCSHSVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
48	N[Nle]D[Nle]RCSASVECKQSCLKAIGSIFGKC[Nle]NKKCKCYPR
49	N[Nle]D[Nle]RCSASVECKQKCKAIGSIFGKC[Nle]NKKCKCYPR
50	NMDMRCSASVECKQKCYKAIGSIFGKCMNKKCKCYPR
51	NMDMRCSASVECKQKCRKAIGSIFGKCMNKKCKCYPR
52	NMDMRCSASVECKQKCLAAIGSIFGKCMNKKCKCYPR
53	NMDMRCSASVECKQKCLYAIGSIFGKCMNKKCKCYPR
54	NMDMRCSASVECKQKCLAIGSIFGKCMNKKCKCYPR
55	NMDMRCSASVECKQKCLKYIGSIFGKCMNKKCKCYPR
56	NMDMRCSASVECKQKCLKRIGSIFGKCMNKKCKCYPR
57	NMDMRCSASVECKQKCLKIGSIFGKCMNKKCKCYPR
58	NMDMRCSASVECKQKCLKAYGSIFGKCMNKKCKCYPR
59	NMDMRCSASVECKQKCLKAEGSIFGKCMNKKCKCYPR
60	NMDMRCSASVECKQKCLKARGSIFGKCMNKKCKCYPR
61	NMDMRCSASVECKQKCLKAGSIFGKCMNKKCKCYPR
62	N[Nle]D[Nle]RCSASVECKQKCLKAIGSPFGKC[Nle]NKKCKCYPR
63	N[Nle]D[Nle]RCSASKECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
64	H[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
65	Y[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
66	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
67	V[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
68	S[Nle]D[Nle]RCSA[Abu]VECKQKCLKAIGSIFGKCMNKKCKCYPR
69	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFG[homo-Lys]CMNKKCKCYPR
70	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-NH2)]PR
71	S[Nle]D[Nle]RCSASVECGQKCLKAIGSIFGKCMNKKCKCYPR
72	S[Nle]D[Nle]RCSASVECVQKCLKAIGSIFGKCMNKKCKCYPR
73	S[Nle]D[Nle]RCSASVECK[2-Amino-5-carboxypentanoyl]KCLKAIGSIFGKCMNKKCKCYPR
74	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKCYQ
75	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCRCYPR
76	S[Nle]DERCSASVECKQKCLKAIGSIFGKCMNKKCKCYPR

77	S[Nle]D[Nle]RCSASVECKQKCLGAIGSIFGKCMNKKCKCYPR
78	S[Nle]D[Nle]RCSASVECKQKCLVAIGSIFGKCMNKKCKCYPR
79	S[Nle]D[Nle]RCSASVECAQSCLKAIGSIFGKCMNKKCKCYPR
80	S[Nle]D[Nle]RCSASVECAQKCLAAIGSIFGKCMNKKCKCYPR
81	S[Nle]D[Nle]RCSASVECAQLCLAAIGSIFGKCMNKKCKCYPR
82	P[Nle]E[Nle]RC[2,4-Diaminobutanoyl]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
83	P[Nle]D[Nle]RCSASVECKQKCLKAIGCIFGKC[Nle]NKKCKCYPC
84	S[Nle]D[Nle]RCSASVECKEKCLQAIGSIFGKC[Nle]NKKCKCYPR
85	P[Nle]D[Nle]RCSASVECKEKCL[homo-Gln]AIGSIFGKC[Nle]NKKCKCYPR
86	CSASVECKQKCLKAIGCIFGKC[Nle]NKKCKCYPC
87	S[Nle]D[Nle]RCSASVECKQKCLAAIGCIFGKC[Nle]NKKCKCYPC
88	P[Nle]E[Nle]RC[2-Amino-3-guanidinopropionyl]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
89	S[Nle]D[Nle]RCSALVECKQKCLKAIGSIFGKCMNKKCKCYPR
90	S[Nle]D[Nle]RCSAVVECKQKCLKAIGSIFGKCMNKKCKCYPR
91	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-F)]PR
92	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-NO_2)]PR
93	S[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKCMNKKCKC[F(4-CH_3)]PR
94	[Nle]D[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
95	NID[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
96	PIE[Nle]RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
97	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
98	P[Nle]E[Nle]RCSA[Orn]VECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
99	P[Nle]E[Nle]RCSASVECKQKCLLAIGSIFGKC[Nle]NKKCKCYPR
100	PIDERCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
101	PIE[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
102	P[Nle]D[Nle]RCSASVECAQKCLAAIGSIFGKCMNKKCKCYPR
103	P[Nle]E[Nle]RCSASVECAQKCLAAIGSIFGKC[Nle]NKKCKCYPR
104	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
105	P[Nle]E[Nle]RC(1)[2,3-Diaminopropanoyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR
106	RCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
107	SKCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
108	LRCSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPR
109	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYPS
110	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYS
111	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCYG
112	CSASVECKQKCLKAIGSIFGKC[Nle]NKKCKCY
113	P[Nle]E[Nle]RC[Orn]ASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
114	P[Nle]E[Nle]RCHASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
115	LRCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
116	LRCSASVECKQKCLAAIGSIFGKCMNKKCKCYPR
117	CSASVECKQKCLKAIGSIFGKCMNKKCKCYPR
118	P[Nle]E[Nle]RCSASVECKEKCLAAIGSIFGKC[Nle]NKKCKCYPR
119	p[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR

120	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYR
121	[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
122	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRR
123	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRY
124	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRL
125	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRH
126	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRE
127	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRKS
128	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRFE
129	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRHR
130	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRAK
131	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYP-[(4-amino-5-hydroxypentyl)guanidine]
132	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR-[4-amino-5-hydroxypentanamide]
133	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRST
134	P[Nle]E[Nle]RCSASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPRRY
135	P[Nle]E[Nle]RCSSSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
136	P[Nle]E[Nle]RCSLSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
137	P[Nle]E[Nle]RCSAPVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
138	P[Nle]E[Nle]RCSASPECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
139	P[Nle]E[Nle]RCSASQECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
140	P[Nle]E[Nle]RCSASVECLQKCLAAIGSIFGKC[Nle]NKKCKCYPR
141	P[Nle]E[Nle]RCSASVECKQPCLAAIGSIFGKC[Nle]NKKCKCYPR
142	P[Nle]E[Nle]RCEASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
143	P[Nle]E[Nle]RCFASVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
144	P[Nle]E[Nle]RCSYSVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
145	P[Nle]E[Nle]RCSAFVECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
146	P[Nle]E[Nle]RCSA[2,3-Diaminopropanoyl]VECKQKCLAAIGSIFGKC[Nle]NKKCKCYPR
147	P[Nle]E[Nle]RC[2,4-Diaminobutanoyl]ASVECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
148	P[Nle]E[Nle]RCRASVECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
149	P[Nle]E[Nle]RCSASRECAQSCLAAIGSIFGKC[Nle]NGKCKCYPR
150	P[Nle]E[Nle]RCSASVECKQKCLAKIGSIFGKC[Nle]NKKCKCYPR

19. The use according to claim 17 or claim 18, wherein the composition comprises one or more peptides wherein the peptides are independently selected from the following peptide sequences:

SEQ ID NO	**Ptd No.**	**Peptide**
1	1	H-QMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
2	2	H-QMDMRC(1)SASVEC(2)KQKC(3)LKAIGRGFGKC(1)MNKKC(2)KC(3)YPR-OH
3	3	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
3	4	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2

4	5	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGRGFGKC(1)MNKKC(2)KC(3)YPR-OH
5	6	H-MDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
6	7	H-DMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
7	8	H-P[Nle]E[Nle]RC(1)YASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
8	9	H-NIDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
9	10	H-NMDVRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
10	11	H-NMDMRC(1)SASVEC(2)KQKC(3)KDAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
11	12	H-GGNMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
12	13	H-NMEMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
13	14	H-SGNMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
14	15	H-N[Nle]DMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
15	16	H-NMD[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
16	17	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
17	18	H-NMDMRC(1)SASVEC(2)KVKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
18	19	H-NMDMRC(1)SASVEC(2)KQLC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
19	20	H-NMDMRC(1)SASVEC(2)KQKC(3)KKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
20	21	H-NMDMRC(1)SASVEC(2)KQKC(3)LDAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
21	22	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIRSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
22	23	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIESIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
23	24	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPRRRTA-NH_2
24	25	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPRHRRK-NH_2
25	26	H-NMDMRC(1)KASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
26	27	H-NMDMRC(1)SISVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
27	28	H-NMDMRC(1)SASREC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
28	29	H-NMDMRC(1)SASVQC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
29	30	H-NMDMRC(1)SASVEC(2)LQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
30	31	H-NMDMRC(1)SASVEC(2)AQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
31	32	H-NMDMRC(1)SASVEC(2)KEKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
32	33	H-NMDMRC(1)SASVEC(2)KLKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
33	34	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIHSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
34	35	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSKFGKC(1)MNKKC(2)KC(3)YPR-NH_2
35	36	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSRFGKC(1)MNKKC(2)KC(3)YPR-NH_2
36	37	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNGKC(2)KC(3)YPR-NH_2
37	38	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)HC(3)YPR-NH_2
38	39	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)VC(3)YPR-NH_2
39	40	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
40	41	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
41	42	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
42	43	H-N[Nle]D[Nle]RC(1)RASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
43	44	H-N[Nle]D[Nle]RC(1)SASVEC(2)EQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2

44	45	H-N[Nle]D[Nle]RC(1)SASVEC(2)QQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
45	46	H-N[Nle]D[Nle]RC(1)SASVEC(2)KKKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
46	47	H-N[Nle]S[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
47	48	H-N[Nle]D[Nle]RC(1)SHSVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
48	49	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQSC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
49	50	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)KAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
50	51	H-NMDMRC(1)SASVEC(2)KQKC(3)YKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
51	52	H-NMDMRC(1)SASVEC(2)KQKC(3)RKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
52	53	H-NMDMRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
53	54	H-NMDMRC(1)SASVEC(2)KQKC(3)LYAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
54	55	H-NMDMRC(1)SASVEC(2)KQKC(3)LAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
55	56	H-NMDMRC(1)SASVEC(2)KQKC(3)LKYIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
56	57	H-NMDMRC(1)SASVEC(2)KQKC(3)LKRIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
57	58	H-NMDMRC(1)SASVEC(2)KQKC(3)LKIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
58	59	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAYGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
59	60	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAEGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
60	61	H-NMDMRC(1)SASVEC(2)KQKC(3)LKARGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
61	62	H-NMDMRC(1)SASVEC(2)KQKC(3)LKAGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
62	63	H-N[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSPFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
63	64	H-N[Nle]D[Nle]RC(1)SASKEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
64	65	H-H[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
65	66	H-Y[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
66	67	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
66	68	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
67	69	H-V[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
68	70	H-S[Nle]D[Nle]RC(1)SA[Abu]VEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
69	71	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFG[homo-Lys]C(1)MNKKC(2)KC(3)YPR-NH_2
70	72	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-NH_2)]PR-NH_2

71	73	H-S[Nle]D[Nle]RC(1)SASVEC(2)GQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
72	74	H-S[Nle]D[Nle]RC(1)SASVEC(2)VQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
73	75	H-S[Nle]D[Nle]RC(1)SASVEC(2)K[2-Amino-5-carboxypentanoyl]KC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
74	76	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YQ-NH_2
75	77	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)RC(3)YPR-NH_2
76	78	H-S[Nle]DERC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
77	79	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LGAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
78	80	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LVAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
79	81	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQSC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
80	82	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
81	83	H-S[Nle]D[Nle]RC(1)SASVEC(2)AQLC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
82	84	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
83	85	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
83	86	H-P[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-OH
84	87	H-S[Nle]D[Nle]RC(1)SASVEC(2)KEKC(3)LQAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
85	88	H-P[Nle]D[Nle]RC(1)SASVEC(2)KEKC(3)L[homo-Gln]AIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
86	89	H-C(1)SASVEC(2)KQKC(3)LKAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
87	90	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGC(4)IFGKC(1)[Nle]NKKC(2)KC(3)YPC(4)-NH_2
88	91	H-P[Nle]E[Nle]RC(1)[2-Amino-3-guanidinopropionyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
89	92	H-S[Nle]D[Nle]RC(1)SALVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
90	93	H-S[Nle]D[Nle]RC(1)SAVVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-NH_2
91	94	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-F)]PR-NH_2
92	95	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-NO_2)]PR-NH_2
93	96	H-S[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)[F(4-CH_3)]PR-NH_2
94	97	H-[Nle]D[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
95	98	H-NID[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
96	99	H-PIE[Nle]RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
97	100	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH

97	101	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
98	102	H-P[Nle]E[Nle]RC(1)SA[Orn]VEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
99	103	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LLAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
100	104	H-PIDERC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
101	105	H-PIE[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
102	106	H-P[Nle]D[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
103	107	H-P[Nle]E[Nle]RC(1)SASVEC(2)AQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
104	108	H-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
104	109	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
105	110	H-P[Nle]E[Nle]RC(1)[2,3-Diaminopropanoyl]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
106	111	H-RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
106	112	Ac-RC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
107	113	Ac-SKC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
108	114	Ac-LRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-NH_2
108	115	H-LRC(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
109	116	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPS-NH_2
110	117	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YS-NH_2
111	118	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YG-NH_2
112	119	Ac-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)[Nle]NKKC(2)KC(3)Y-NH_2
113	120	H-P[Nle]E[Nle]RC(1)[Orn]ASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
114	121	H-P[Nle]E[Nle]RC(1)HASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
115	122	Ac-LRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
116	123	Ac-LRC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
117	124	H-C(1)SASVEC(2)KQKC(3)LKAIGSIFGKC(1)MNKKC(2)KC(3)YPR-OH
118	125	H-P[Nle]E[Nle]RC(1)SASVEC(2)KEKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
119	126	H-p[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
120	127	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YR-OH
121	128	H-[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
122	129	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRR-OH
123	130	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRY-OH

124	131	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRL-OH
125	132	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRH-OH
126	133	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRE-OH
127	134	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRKS-OH
128	135	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRFE-OH
129	136	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRHR-OH
130	137	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRAK-OH
131	138	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YP-[(4-amino-5-hydroxypentyl)guanidine]
132	139	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-[4-amino-5-hydroxypentanamide]
133	140	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRST-OH
134	141	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPRRY-OH
135	142	H-P[Nle]E[Nle]RC(1)SSSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
136	143	H-P[Nle]E[Nle]RC(1)SLSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
137	144	H-P[Nle]E[Nle]RC(1)SAPVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
138	145	H-P[Nle]E[Nle]RC(1)SASPEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
139	146	H-P[Nle]E[Nle]RC(1)SASQEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
140	147	H-P[Nle]E[Nle]RC(1)SASVEC(2)LQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
141	148	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQPC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
142	149	H-P[Nle]E[Nle]RC(1)EASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
143	150	H-P[Nle]E[Nle]RC(1)FASVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH

144	151	H-P[Nle]E[Nle]RC(1)SYSVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
145	152	H-P[Nle]E[Nle]RC(1)SAFVEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
146	153	H-P[Nle]E[Nle]RC(1)SA[2,3-Diaminopropanoyl]VEC(2)KQKC(3)LAAIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH
147	154	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-OH
147	155	H-P[Nle]E[Nle]RC(1)[2,4-Diaminobutanoyl]ASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
148	156	H-P[Nle]E[Nle]RC(1)RASVEC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
149	157	H-P[Nle]E[Nle]RC(1)SASREC(2)AQSC(3)LAAIGSIFGKC(1)[Nle]NGKC(2)KC(3)YPR-NH_2
150	158	H-P[Nle]E[Nle]RC(1)SASVEC(2)KQKC(3)LAKIGSIFGKC(1)[Nle]NKKC(2)KC(3)YPR-OH